Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
暂无分享,去创建一个
V. Haufroid | S. Broutin | J. Guitton | D. Richard | B. Royer | M. Etienne-Grimaldi | J. Ciccolini | E. Gautier‐Veyret | F. Thomas | Antonin Schmitt | C. Narjoz | M. Launay | C. Tron | F. Le Louedec | Hugo Alarcan | N. Tafzi | Maud Maillard
[1] J. Phelip,et al. Clinical considerations for DPD deficiency testing in advanced cancer patients: tumor lysis syndrome should be considered as a major interference. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. V. van Kuilenburg,et al. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study , 2022, Clinical pharmacology and therapeutics.
[3] H. Stepman,et al. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma , 2022, Clinical chemistry and laboratory medicine.
[4] M. Loriot,et al. Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results , 2021, Cancer Chemotherapy and Pharmacology.
[5] J. Guitton,et al. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature , 2021, ESMO open.
[6] Jacob E. Wulff,et al. Global biochemical analysis of plasma, serum and whole blood collected using various anticoagulant additives , 2021, PloS one.
[7] V. Haufroid,et al. Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Loriot,et al. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency , 2020, British Journal of Cancer.
[9] P. Marquet,et al. Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS/MS for prevention of toxicity and dose adjustment of fluoropyrimidines. , 2020, Therapeutic drug monitoring.
[10] C. Solas,et al. A Simple and Rapid UPLC‐UV Method for Detecting DPD Deficiency in Patients With Cancer , 2020, Clinical and translational science.
[11] G. Defossez,et al. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. , 2019, European journal of cancer.
[12] M. Loriot,et al. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. , 2019, Bulletin du cancer.
[13] J. Schellens,et al. Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers , 2018, British journal of clinical pharmacology.
[14] J. Schellens,et al. The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases , 2018, European Journal of Clinical Pharmacology.
[15] C. Florkowski,et al. evelopment , validation and application of a novel liquid hromatography tandem mass spectrometry assay measuring uracil , , 6-dihydrouracil , 5-fluorouracil , 5 , 6-dihydro-5-fluorouracil ,-fluoro-- ureidopropionic acid and-fluoro-- alanine in human lasma , 2017 .
[16] J. Schellens,et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity , 2017, British Journal of Cancer.
[17] J. Schellens,et al. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. , 2016, British journal of clinical pharmacology.
[18] J. Schellens,et al. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. , 2016, Journal of pharmaceutical and biomedical analysis.
[19] J. Sanderson,et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.
[20] G. Schwartsmann,et al. Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase. , 2015, Clinical biochemistry.
[21] J. Schellens,et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. , 2015, Pharmacogenomics.
[22] A. V. van Kuilenburg,et al. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. , 2014, Pharmacogenomics.
[23] U. Amstutz,et al. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. , 2013, Biomedical chromatography : BMC.
[24] M. Loriot,et al. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma. , 2012, Journal of chromatographic science.
[25] G. A. Pianetti,et al. A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer , 2012, Therapeutic drug monitoring.
[26] Fabio Garofolo,et al. Impact of plasma and whole-blood anticoagulant counter ion choice on drug stability and matrix effects during bioanalysis. , 2009, Bioanalysis.
[27] M. Egorin,et al. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. , 2008, Rapid communications in mass spectrometry : RCM.
[28] E. Gamelin,et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. , 2007, Cancer letters.
[29] R. Diasio,et al. Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians , 2006, Clinical Cancer Research.
[30] E. Gamelin,et al. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[31] Hao Jiang,et al. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels , 2004, British journal of pharmacology.
[32] A. V. van Kuilenburg. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. , 2004, European journal of cancer.
[33] J. Leffert,et al. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. , 2002, Biochimica et biophysica acta.
[34] O. Dassonville,et al. [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.